Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

ClinicalTrials.gov ID: NCT07009860

Public ClinicalTrials.gov record NCT07009860. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 7, 2026, 12:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

RESTORE TRIAL: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in subjects with ALD.

Study identification

NCT ID
NCT07009860
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Altimmune, Inc.
Industry
Enrollment
121 participants

Conditions and interventions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 15, 2025
Primary completion
Sep 29, 2027
Completion
Sep 29, 2027
Last update posted
Aug 16, 2026

2025 – 2027

United States locations

U.S. sites
36
U.S. states
15
U.S. cities
33
Facility City State ZIP Site status
Altimmune Clinical Study Site Peoria Arizona 85381
Altimmune Clinical Study Site Tucson Arizona 85712
Altimmune Clinical Study Site North Little Rock Arkansas 72117
Altimmune Clinical Study Site Fresno California 93720
Altimmune Clinical Study Site La Jolla California 92037
Altimmune Clinical Study Site Pasadena California 91105
Altimmune Clinical Study Site Bradenton Florida 34201
Altimmune Clinical Study Site Doral Florida 33122
Altimmune Clinical Study Site Fort Myers Florida 33192
Altimmune Clinical Study Site Miami Florida 33125
Altimmune Clinical Study Site Miami Florida 33165
Altimmune Clinical Study Site Miami Lakes Florida 33122
Altimmune Clinical Study Site Naples Florida 34102
Altimmune Clinical Study Site Orlando Florida 32803
Altimmune Clinical Study Site Atlanta Georgia 30309
Altimmune Clinical Study Site Indianapolis Indiana 46202
Altimmune Clinical Study Site Louisville Kentucky 40202
Altimmune Clinical Study Site Bastrop Louisiana 71220
Altimmune Clinical Study Site Marrero Louisiana 70072
Altimmune Clinical Study Site West Monroe Louisiana 71291
Altimmune Clinical Study Site St Louis Missouri 63123
Altimmune Clinical Study Site Las Vegas Nevada 89106
Altimmune Clinical Study Site Manhasset New York 11030
Altimmune Clinical Study Site New York New York 10032
Altimmune Clinical Study Site Syracuse New York 13210
Altimmune Clinical Study Site Wilmington North Carolina 28403
Altimmune Clinical Study Site Westlake Ohio 44145
Altimmune Clinical Study Site Brownsville Texas 78520
Altimmune Clinical Study Site Dallas Texas 75390
Altimmune Clinical Study Site Edinburg Texas 78539
Altimmune Clinical Study Site Houston Texas 77030
Altimmune Clinical Study Site Houston Texas 77079
Altimmune Clinical Study Site San Antonio Texas 78215
Altimmune Clinical Study Site San Antonio Texas 78251
Altimmune Clinical Study Site Waco Texas 76710
Altimmune Clinical Study Site Seattle Washington 98105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07009860, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 16, 2026 · Synced Sep 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07009860 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →